Romain Séchaud

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

Eric Nisbet‐Brown, Nancy F. Olivieri, Patricia J. Giardina et al. · The Lancet · 2003 · 330 citations

Medicine, Hematology, Pharmacology +12

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

Antonio Piga, Renzo Galanello, Maria Domenica Cappellini et al. · PubMed · 2006 · 269 citations · Full text

Medicine, Hematology, Pharmacology +17

Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.

Renzo Galanello, Antonio Piga, Daniele Alberti et al. · PubMed · 2003 · 171 citations

Medicine, Pharmacokinetics, Pharmacology +17

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.

Renzo Galanello, Antonio Piga, Yves Bertrand et al. · PubMed · 2006 · 139 citations

Medicine, Hematology, Pharmacology +17

Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron‐Chelating Agent in Patients with Transfusion‐Dependent Iron Overload Due to β‐Thalassemia

Renzo Galanello, Antonio Piga, Daniele Alberti et al. · The Journal of Clinical Pharmacology · 2003 · 131 citations

Medicine, Pharmacokinetics, Pharmacology +17